Companion Medical’s InPen Diabetes Management System Receives the US FDA’s Approval for Fixed Dosing and Meal Estimation

 Companion Medical’s InPen Diabetes Management System Receives the US FDA’s Approval for Fixed Dosing and Meal Estimation

Companion Medical’s InPen Diabetes Management System Receives the US FDA’s Approval for Fixed Dosing and Meal Estimation

Shots:

  • The InPen bolus calculator determines the user’s current glucose level and active insulin to calculate the amount of insulin still lowering glucose from previous bolus doses thus removing the conjecture from insulin dosing
  • The new InPen offers users on fixed-dose or meal estimation therapy an advance solution to maintain blood glucose level and avoid stacking of insulin and minimizing the risk of low glucose. The device is cleared for both T1D & T2D patients who administer insulin for meals or deliver doses based on the approximate size of their planned meal
  • The InPen system includes a smartpen and Bluetooth connected app that aid in calculating insulin doses, issues dose reminders, track active insulin and send reports to caregivers and is available in the US The InPen system includes a smartpen and Bluetooth connected app that aid in calculating insulin doses, issues dose reminders, track active insulin and send reports to caregivers and is available in the US The InPen system includes a smartpen and Bluetooth connected app that aid in calculating insulin doses, issues dose reminders, track active insulin and send reports to caregivers and is available in the US

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: InPen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post